Nothing said here yet.
to join the conversation.
LOS GATOS, CA / ACCESS Newswire / October 29, 2026 / , Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients with sacro-pelvic disorders, today announced plans to release financial results for the third quarter ended September…
~ New decortication system is the latest advancement in Tenon's next-generation SI joint fusion platform with additional innovative product launches expected in the coming quarters ~~ Quickstep Decorticator designed to streamline joint decortication and…
~Newly issued patents continue to solidify the company's position as an innovator in the rapidly growing sacro-pelvic fusion market~~Portfolio now includes 38 issued U. patents and 9 international patents, with 31 applications pending~~Company anticipates…
~ SImmetry+ System generated approximately $1.2 million in incremental revenue during limited launch period ~~ Company plans to support anticipated demand for the SImmetry+ System by expanding its instrument set inventory as needed ~~ New SImmetry+ 3D printed…
WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Tenon Medical, Inc.
LOS GATOS, CA / ACCESS Newswire / September 14, 2026 / , Inc.
WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Tenon Medical, Inc.
LOS GATOS, CA / ACCESS Newswire / September 11, 2026 / , Inc.
~ Company Takes Proactive Step to Strengthen Balance Sheet and Maintain Flexibility to Execute on Continued Business Momentum ~LOS GATOS, CA / ACCESS Newswire / September 9, 2026 / , Inc.
LOS GATOS, CA / ACCESS Newswire / August 31, 2026 / , Inc.
WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that on August 27, 2026, Tenon Medical, Inc.
LOS GATOS, CA / ACCESS Newswire / August 28, 2026 / (NASDAQ:TNON), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced that on August 27, 2026 it has entered into a securities purchase agreement with an institutional investor to sell 597,610 shares of common stock (or pre-funded warrants in lieu thereof), together with a warrant to purchase up to an aggregate 1,058,517 shares of common stock, in a private placement offering.